Barrier Therapeutics Announces Agreement with Procter & Gamble to Market Xolegel (ketoconazole,...
primenewswire.com     May 22, 2008            

PRINCETON, N.J., May 22, 2008 (PRIME NEWSWIRE) -- Barrier Therapeutics, Inc. (Nasdaq:BTRX), a pharmaceutical company developing and commercializing products in the field of therapeutic dermatology, announced that it will package its seborrheic dermatitis treatment Xolegel(r) (ketoconazole, USP)... [read full story]                

Add a comment to the article
Type the code shown

View all news articles about:

- Related Topics

View other selected articles:

                   

Men’s Skin Care

myrxpill.com     11 hrs ago   1 related          

A Gift for Your Favorite Guy If you’re like a lot of women I know, you have a perennial problem: Gift ideas for men can be hard to find. Ties, tools, gadgets - there’s only so many times you can go there! Want to think outside...                

comments

                   

CombinatoRx Highlights Progress in Key Programs at 2008 R& D Day

genengnews.com     13 hrs ago          

News source: Business Wire CombinatoRx, Incorporated today provided a detailed review of selected therapeutic programs and a general company update at its annual Research and Development (R&D) day at its corporate headquarters...                

comments

                   

Sunscreen safety is called into question

iht.com     21 hrs ago   2 related          

For years, dermatologists have told us sunscreen protects skin. Now, many people are questioning that advice after an environmental group challenged the safety of many popular brands. "Patients are confused," said Darrell...                

comments

Host-derived oxidized phospholipids and HDL regulate innate immunity in human leprosy.

biowizard.com     yesterday          

Division of Cardiology, Molecular Biology Institute, Department of Microbiology, Immunology, and Molecular Genetics, and Division of Dermatology, Department of Medicine, UCLA David Geffen School of Medicine, Los Angeles,...                

comments